{"id":"NCT00887250","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Investigate the Antihypertensive Efficacy of MK0954","officialTitle":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan (MK954, DuP753) in Patients With Mild to","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1991-12","primaryCompletion":"1992-08","completion":"1992-11","firstPosted":"2009-04-23","resultsPosted":"2009-06-24","lastUpdate":"2009-07-14"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"losartan potassium","otherNames":["MK0954"]},{"type":"DRUG","name":"Comparator: losartan","otherNames":["MK0954"]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension.","primaryOutcome":{"measure":"Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12","timeFrame":"At baseline and at 12 weeks (24 hours post dose)","effectByArm":[{"arm":"Placebo","deltaMin":-4.3,"sd":6.7},{"arm":"Losartan 50 mg","deltaMin":-7.9,"sd":7.6},{"arm":"Losartan 50/100 mg","deltaMin":-8.6,"sd":7.7}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}